NASDAQ: ACET
Adicet Bio, Inc.
Healthcare · Biotechnology
After hours: $8.45(+0.84%) · as of 7:34 PM ET
Market Cap
$78.34M
52w High
$17.44
52w Low
$6.01
P/E
-0.73
Volume
57.53K
Outstanding Shares
9.35M
Performance
Return analysis
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 19.42% over the last year. Free cash flow grew 15.25% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read is wrong if revenue rolls over, margins compress again, or free cash flow keeps deteriorating. In that case the selloff would be catching up with weaker business quality rather than just a lower multiple.
Company profile
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases.
Valuation
Stock splits
Every 16 shares became 1
Every 7 shares became 1
Profitability & growth
Analyst consensus
9
Buy
3
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 4, 2026
Q4 FY26 · EPS est -$1.39 · Revenue est —
View